混合治疗(手术联合放射外科)治疗肾细胞癌脊柱转移瘤
这项回顾性研究分析了2003至2017年间接受分离手术联合辅助立体定向体部放疗(SBRT)的90例肾细胞癌脊柱转移患者,其中高分级硬膜外脊髓压迫(ESCC 2级和3级)患者占多数。结果显示1年主要并发症累积发生率为3.4%,1年局部控制率为95.4%,中位总生存期为14.8个月。作者认为混合治疗是安全有效的策略。
要点
- 90例肾细胞癌脊柱转移患者接受分离手术联合SBRT,均为ESCC 2级或3级。
- 1年主要并发症累积发生率为3.4%(95%CI:0.0%-7.2%)。
- 1年局部控制率为95.4%(95%CI:91.0%-99.8%),中位总生存期14.8个月。
核心结论
- 这些数据支持使用混合治疗作为肾细胞癌脊柱转移的安全有效策略。
研究设计与样本
- 回顾性研究,基于前瞻性收集的2003年至2017年间接受混合治疗(分离手术联合辅助立体定向体部放疗)的肾细胞癌脊柱转移患者队列。
- 共纳入90例患者,SBRT方式包括高剂量单次、高剂量大分割和低剂量大分割。
主要发现
- 转移灶为广泛性、寡转移性和孤立性者分别占56%、33%和11%。
- SBRT采用高剂量单次、高剂量大分割和低剂量大分割者分别占24%、56%和20%。
- 1年主要并发症累积发生率为3.4%(95%CI:0.0%-7.2%)。
- 全队列中位随访14.2个月,生存者中位随访38.3个月。
- 1年进展累积发生率为4.6%(95%CI:0.2%-9.0%),即术后1年局部控制率为95.4%(95%CI:91.0%-99.8%)。
临床怎么用
- 原文结论支持将混合治疗作为肾细胞癌脊柱转移的安全有效策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of spinal metastatic renal cell carcinoma (mRCC) is controversial regarding extent of resection and radiation dosing. OBJECTIVE: To determine outcomes in patients treated with hybrid therapy (separation surgery plus adjuvant stereotactic body radiation therapy [SBRT]) for mRCC. METHODS: A retrospective study of a prospectively collected cohort of patients undergoing hybrid therapy for mRCC between 2003 and 2017 was performed. SBRT was delivered as high-dose single-fraction, high-dose hypofractionated, or low-dose hypofractionated. Extent of disease, clinical and operative outcomes, and complications data were collected, and associations with overall survival (OS) and progression-free survival were determined. RESULTS: Ninety patients with mRCC with high-grade epidural spinal cord compression (ESCC grades 2 and 3) were treated. Metastases were widespread, oligometastatic, and solitary in 56%, 33%, and 11% of patients, respectively. SBRT delivered was high-dose single-fraction, high-dose hypofractionated, and low-dose hypofractionated in 24%, 56%, and 20% of patients, respectively. The 1-yr cumulative incidence of major complications was 3.4% (95% confidence interval [CI]: 0.0%-7.2%). The median follow-up was 14.2 mo for the entire cohort and 38.3 mo for survivors. The 1-yr cumulative incidence of progression was 4.6% (95% CI: 0.2%-9.0%), which translates to a local control rate of 95.4% (95% CI: 91.0%-99.8%) 1 yr after surgery. The median OS for the cohort was 14.8 mo. CONCLUSION: These data support the use of hybrid therapy as a safe and effective strategy for the treatment of renal cell spine metastases.
引用
- Hussain I, Goldberg JL, Carnevale JA, et al. Hybrid Therapy (Surgery and Radiosurgery) for the Treatment of Renal Cell Carcinoma Spinal Metastases. Neurosurgery. 2022. PMID: 35023875. doi:10.1227/NEU.0000000000001780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。